Biocon to market new breast cancer drug in India

" 'Though cancer rates in India are lower than those in western countries, the cases are rising due to early detection and increasing migration of rural population to cities, increasing life expectancy and changing lifestyles. " Bangalore, July 18 - Biotechnology major Biocon Ltd will market Abraxane drug of the US-based Abraxis BioScience in India for treating breast cancer, a top company official said here Friday. To be priced at about $400 - per 100mg vial in India, the drug will be cheaper by 60 percent than in the US where it is sold at $1,000 - per vial of same measure. Abraxane will be the second oncotherapeutics drug Biocon will be marketing after the launch of its proprietary antibody Biomab for the treatment of head and neck cancers. 'Abraxane is the first albumin-bound taxane particle of 130 nanometres that takes... [read full story]